Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Nasdaq

Upland Software's Return On Capital Employed Overview

Upland Software (NASDAQ:UPLD) brought in sales totaling $78.72 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 205.59%, resulting in a loss of $22.83 million.

Benzinga

Carlyle Group's Return On Capital Employed Overview

Pulled from Benzinga Pro data, Carlyle Group (NASDAQ:CG) posted Q1 earnings of $594.80 million, an increase from Q4 of 9.93%. Sales dropped to $779.50 million, a 58.87% decrease between quarters.

Benzinga

eXp World Holdings Earnings Perspective: Return On Capital Employed

According to Benzinga Pro, during Q1, eXp World Holdings (NASDAQ:EXPI) earned $8.86 million, a 42.65% increase from the preceding quarter. eXp World Holdings's sales decreased to $1.01 billion, a 6.13% change since Q4.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Looking Into Morphic Holding's Return On Capital Employed

Benzinga Pro data, Morphic Holding (NASDAQ:MORF) reported Q1 sales of $2.38 million. Earnings fell to a loss of $31.48 million, resulting in a 47.11% decrease from last quarter.

Benzinga

Looking Into Tellurian's Return On Capital Employed

Benzinga Pro data, Tellurian (NASDAQ:TELL) reported Q1 sales of $146.94 million. Earnings fell to a loss of $66.61 million, resulting in a 61.57% decrease from last quarter.

Benzinga

Ionis Pharmaceuticals Earnings Perspective: Return On Capital Employed

Benzinga Pro data, Ionis Pharmaceuticals (NASDAQ:IONS) reported Q1 sales of $142.00 million. Earnings fell to a loss of $65.17 million, resulting in a 129.01% decrease from last quarter.

Benzinga

Pacira BioSciences's Return on Invested Capital Overview

Pulled from Benzinga Pro data, Pacira BioSciences (NASDAQ:PCRX) posted Q1 earnings of $6.83 million, an increase from Q4 of 233.1%. Sales dropped to $157.99 million, a 0.76% decrease between quarters.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Vericel Earnings Perspective: Return On Capital Employed

Benzinga Pro data, Vericel (NASDAQ:VCEL) reported Q1 sales of $36.07 million. Earnings fell to a loss of $7.09 million, resulting in a 256.4% decrease from last quarter. Vericel earned $4.53 million, and sales totaled $47.59 million in Q4.

Benzinga

Menarini, Radius Health's Elacestrant Prolongs Progression Free Survival In Breast Cancer

The Menarini Group and Radius Health Inc's (NASDAQ: RDUS) data from the phase 3 EMERALD trial evaluating elacestrant for ER+/HER2- advanced or metastatic breast cancer were published in the Journal of Clinical Oncology.

Benzinga

What's The Future For Cannabis-Infused Edibles?

Cannabis-infused edibles are a booming market. The near-endless array of cannabinoid-rich foods and beverages are coupled with positive sales figures, suggesting that edibles should stick around as a market leader in the years to come.

Benzinga

Why Palo Alto Networks Stock Is Moving Higher

Palo Alto Networks Inc (NASDAQ: PANW) shares are trading higher Friday after the company reported better-than-expected financial results and raised guidance.

Benzinga

Jim Cramer Says This Company Is Losing Money

On CNBC’s "Mad Money Lightning Round," Jim Cramer said PLBY Group, Inc. (NASDAQ: PLBY) is losing money and he doesn’t want to touch companies that are losing money.

Benzinga

Expert Ratings for Costco Wholesale

Analysts have provided the following ratings for Costco Wholesale (NASDAQ:COST) within the last quarter:

Benzinga

Analyst Ratings for Arvinas

Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter:

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Morning Brief: Top Financial Stories Dominating on Friday, May 20

Reuters

Benzinga

The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

4 Stocks Under $2 Insiders Are Aggressively Buying

US stock futures traded higher this morning on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or…

Benzinga

10 Biggest Price Target Changes For Friday

Telsey Advisory Group lowered the price target for Best Buy Co., Inc. (NYSE: BBY) from $130 to $90. Best Buy shares rose 0.4% to $73.58 in pre-market trading.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Dogecoin Daily: Dogecoin In The Green Amid Stock Meltdown, Foundation Artist Thanks Vitalik Buterin For $1M Donation

Dogecoin (CRYPTO: DOGE) rose nearly 1% higher to 9 cents over the 24 hours leading up to early Friday morning. DOGE rose alongside other major coins as the global cryptocurrency market cap rose 2.3% to $1.3 trillion at press time.

Benzinga

Here's How Microsoft Addressed Complaints From Smaller European Cloud Companies

Microsoft Corp's (NASDAQ:MSFT) pitch to Brussels directly addressed competition worries with a clear geopolitical purpose prompted by recent complaints from smaller European cloud companies, the Financial Times reports. Microsoft laid out a series of "principles" that it would follow out of respect for Europe's concerns. Any customer who has paid to license…

Benzinga

Executives Sell More Than $260M Of 3 Stocks

US crude oil futures traded higher this morning on Friday. Investors, meanwhile, focused on some notable insider trades.

Benzinga

EXCLUSIVE: Mondee Registers 179% Revenue Growth In Q1 Aided By Post-Pandemic Travel Recovery; Upsizes PIPE Commitment By $20M

Mondee Inc, the high-growth travel technology company and marketplace with a portfolio of globally recognized platforms and brands in the leisure and corporate travel sectors, announced financial results for the first quarter ended March 31, 2022.

Benzinga

Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara

Atara Biotherapeutics Inc (NASDAQ:ATRA) received notification that Bayer AG's (OTC:BAYRY) intends to end the exclusive worldwide licensing agreement for mesothelin-directed CAR T-cell therapies. The collaboration included the funding and development of ATA3271, allogeneic T-cell immunotherapy, and an autologous version, ATA2271, for high mesothelin-expressing tumors. ATA3271 leverages Atara's EBV T-cell platform and is currently in IND…

Benzinga

Coinbase And 2 Other Stocks Insiders Are Buying

Although the Dow Jones dropped by over 200 points on Thursday, there were a few notable insider trades.

Benzinga

FDA Places Clinical Hold On Foghorn Therapeutics' Early-Stage Blood Cancer Trial

The FDA has instituted a clinical hold on Foghorn Therapeutics Inc's (NASDAQ:FHTX) Phase 1 dose-escalation study of FHD-286 in relapsed and/or refractory acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). The FDA initiated the partial clinical hold following the report of a recent death that occurred in a subject with potential differentiation syndrome. Differentiation…

1 … 468 469 470 471

People

FrancoisPhilippe Champagne

12 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.